Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Brace Pharma Capital is a venture capital firm established by EMS S/A, Brazil's largest pharmaceutical company, alongside high net worth biotech investors. The firm specializes in global investments within the biotechnology and healthcare sectors, focusing on innovative therapies. They manage a portfolio of 10 companies, targeting diseases with high unmet medical needs.
Brace Pharma Capital invests in innovative therapies that address significant unmet medical needs, particularly in the biotech and pharmaceutical sectors. Their investment strategy emphasizes life-changing treatments, with a keen interest in therapies for cancer, genetic disorders, and infectious diseases.
Notable portfolio companies include Avidity Biosciences (NASDAQ: RNA), developing antibody-siRNA conjugates; AVROBIO (NASDAQ: AVRO), focused on lentiviral-based gene therapies; and Precision Biosciences (NASDAQ: DTIL), which is advancing ARCUS genome editing technologies. Other companies include Zymeworks (NYSE: ZYME), Antiva Biosciences, F2G, Gliknik, Navitor Pharmaceuticals, ReViral, Turnstone Biologics, and Vero Biotech.
Email your pitch deck to info@bracepharma.com for consideration.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.